


IAP3 Rec'd PCT/PTO 13 JAN 2006



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	10/534,082	Art Unit:	tba
Filed:	05/05/05	Examiner:	tba
1 <sup>st</sup> Inventor:	HINUMA, Shuji	Allowed:	
For:	Novel FPRLI Ligands and Use Thereof	Batch:	
Atty. Dkt. No.	3118 USOP	Paper No.:	

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EV 684083900 US

DATE IN: January 12, 2006  
3

Itemized Papers/Items:

1. This Certificate of Express Mailing and Return Postcard and (2 pages)
2. Transmittal Form (1 page X 2)
3. Response to Notice of Missing Requirements and Notice to Comply with Sequence Listing Requirements (2 pages), Submission of written Sequence Listing (10 pages), IBM PC/AT format disk containing the CRF of the Sequence Listing, and copy of Notification of Missing Parts (6 pages)
4. Copies of previously submitted statement of Submission of Executed Declaration (1 page); executed Declaration (7 pages); fee transmittal form (1 page); transmittal form (1 page); Express Mail Receipt (1 page); stamped received postcard (1 page; Certificate of Express Mailing (1 page)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

MAIL STOP MISSING PARTS  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on this date, 1/12/06

Dated: 1/12/06

*Gail L. Winokur*  
Gail L. Winokur

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
475 Half Day Road  
Lincolnshire, IL 60069 USA



PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/534,082
		Filing Date	05/05/05
		First Named Inventor	HINUMA, Shuji
		Art Unit	tba
		Examiner Name	tba
Total Number of Pages in This Submission	35	Attorney Docket Number	3118 USOP

### ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below):  Return Postcard; Cert. of Exp. Mailing; Written Seq. Listing; CRF of Seq. Listing; Copy of Notification; Copies of previously submitted documents
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input checked="" type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		
The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 500799.		

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name			
Signature	<i>Mark Chao/glw</i>		
Printed name	Mark Chao		
Date	1/12/2006	Reg. No.	37,293

### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: *Express*

Signature	<i>Gail L. Winokur</i>		
Typed or printed name	Gail L. Winokur	Date	1/12/2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

*Express Mail No. EV 68408390045*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/534,082

Filed: 05/05/05

1<sup>st</sup> Inventor: HINUMA, Shuji

For: Novel FPRLI Ligands and Use Thereof

Atty. Dkt. No. 3118 USOP



Art Unit: tba

Examiner: tba

Allowed:

Batch:

Paper No.:

Response to Notice of Missing Requirements and  
Notice to Comply with Sequence Listing Requirements

**MAIL STOP FORMALITIES**

Commissioner for Patents

P.O. Box 1450

Arlington, VA 22313-1450

Sir:

In response to the Notice of Missing Requirements mailed 01/05/06, and to comply with the current sequence listing rules.

**REMARKS**

1. Oath or Declaration of Inventors

Applicants have previously submitted a copy of the executed Declaration of Inventors identifying the priority documents by serial number and filing date by Express Mail on 12/12/05.

Applicants herewith provide a new copy of the executed Declaration, along with a copy of the certificate of mailing and Express Mail receipt and USPTO date stamped return postcard acknowledging receipt.

The Commissioner is authorized to charge any appropriate fees to the Applicant's USPTO Deposit Account 500799.

## 2. Sequence Listing Errors in CRF

Applicants respectfully submit, along with a copy of the Notice, a substitute written Sequence Listing and a DOS Text CRF Sequence Listing file "3118us0p.seq.txt" on the enclosed 3.5" IBM PC/AT computer disk.

Please substitute the Written Sequence Listing for the Sequence Listing as filed.

Applicants have corrected SEQ ID NO.: 2 in the CRF to include a missing LYS at position 144, which was inadvertently left out.

The full amino acid sequence for SEQ ID NO.: 2 is shown on Page 2 of the Written Sequence listing as originally filed. Further support for this is found in SEQ ID NO.: 3, which is now formatted using PATENTIN 3.0 to concurrently show the translated amino acid sequence, which is SEQ ID NO.: 2.

Applicants have inserted the current application data to the sequence listing heading, and the current docket number for identification purposes.

The undersigned hereby certifies that the CRF and the written Sequence Listing are the same in content. The substitute Sequence Listing contains no new matter.

Respectfully submitted,



Dated: January 11, 2006

(847)383-3372

(847)383-3391

Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43032

Attorney for Applicants

Customer No. 23115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
475 Half Day Road  
Lincolnshire, IL 60069 USA

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/534,082  
Filed: 05/05/2005  
1<sup>st</sup> Inventor: S. Hinuma  
For: Novel FPRLI Ligands and Use Thereof  
Atty. Dkt. No. 3118 USOP

Art Unit: tba  
Examiner: tba  
Allowed:  
Batch:  
Paper No.:

**Submission of Executed Declaration**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants herewith submit a true and correct copy of the duly executed Declaration of the inventors for the above-identified application.


Also enclosed is a true and correct copy of the Assignment, and Assignment Recordation Cover Sheet.

Applicants herewith authorize the Commission to charge the Applicants' USPTO deposit account No. 500799 for any fees deemed appropriate.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, he is respectfully requested to call applicants' attorney at (847) 383-3372.

Respectfully submitted,

Dated: December 2, 2005




Mark Chao, Ph.D., Reg. No. 37,293  
Elaine M. Ramesh, Ph.D., Reg. No. 43,032  
Attorney for Applicants  
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
475 Half Day Road  
Lincolnshire, IL 60069 USA

**DUPLICATE**

**DUPLICATE**

372 Def



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/534,082	Shuji Hinuma	3118 USOP

INTERNATIONAL APPLICATION NO.

PCT/JP03/14138

I.A. FILING DATE	PRIORITY DATE
11/06/2003	11/07/2002

23115  
TAKEDA PHARMACEUTICALS NORTH AMERICA, INC  
INTELLECTUAL PROPERTY DEPARTMENT  
475 HALF DAY ROAD  
SUITE 500  
LINCOLNSHIRE, IL 60069

CONFIRMATION NO. 9415

371 FORMALITIES LETTER




\*OC000000017760283\*

Date Mailed: 01/05/2006

### NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 05/05/2005
- English Translation of the IA filed on 05/05/2005
- Copy of the International Search Report filed on 05/05/2005
- Copy of IPE Report filed on 05/05/2005
- Preliminary Amendments filed on 05/05/2005
- Information Disclosure Statements filed on 05/05/2005
- Biochemical Sequence Diskette filed on 05/05/2005
- Biochemical Sequence Listing filed on 05/05/2005
- U.S. Basic National Fees filed on 05/05/2005
- Priority Documents filed on 05/05/2005
- Specification filed on 05/05/2005
- Claims filed on 05/05/2005
- Abstracts filed on 05/05/2005
- Drawings filed on 05/05/2005
- Paper nucleotide sequence listings filed on 05/05/2005



The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a

substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

**ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

**For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:**

- **For Rules Interpretation, call (571) 272-0951**
- **For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
- **Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)**

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

INDIA L EVANS

---

Telephone: (703) 308-9140 EXT 212

**PART 1 - ATTORNEY/APPLICANT COPY**

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/534,082	PCT/JP03/14138	3118 USOP

FORM PCT/DO/EO/905 (371 Formalities Notice)

# DUPLICATE

PTO/SB/17 (10-04)

Approved for use through 07/31/2006. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## FEE TRANSMITTAL for FY 2005

*Effective 10/01/2004. Patent fees are subject to annual revision.*

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT	(\$)	130.00
-------------------------	------	--------

### Complete if Known

Application Number	10/534,082
Filing Date	05/05/2005
First Named Inventor	S. Hinuma
Examiner Name	tba
Art Unit	tba
Attorney Docket No.	3118 USOP

### METHOD OF PAYMENT (check all that apply)

Check  Credit card  Money Order  Other  None

Deposit Account:

Deposit Account Number	500799
Deposit Account Name	Takeda Pharmaceutical Company Limited

The Director is authorized to: (check all that apply)

Charge fee(s) indicated below  Credit any overpayments  
 Charge any additional fee(s) or any underpayment of fee(s)  
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

### FEE CALCULATION (continued)

#### 3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Description			Fee Paid
Fee Code (\$)	Fee Code (\$)	Fee Code (\$)	Fee Description		
1051 130	2051 65	2051 65	Surcharge - late filing fee or oath		130.00
1052 50	2052 25	2052 25	Surcharge - late provisional filing fee or cover sheet		
1053 130	1053 130	1053 130	Non-English specification		
1812 2,520	1812 2,520	1812 2,520	For filing a request for <i>ex parte</i> reexamination		
1804 920*	1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action		
1805 1,840*	1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action		
1251 110	2251 55	2251 55	Extension for reply within first month		
1252 430	2252 215	2252 215	Extension for reply within second month		
1253 980	2253 490	2253 490	Extension for reply within third month		
1254 1,530	2254 765	2254 765	Extension for reply within fourth month		
1255 2,080	2255 1,040	2255 1,040	Extension for reply within fifth month		
1401 340	2401 170	2401 170	Notice of Appeal		
1402 340	2402 170	2402 170	Filing a brief in support of an appeal		
1403 300	2403 150	2403 150	Request for oral hearing		
1451 1,510	1451 1,510	1451 1,510	Petition to institute a public use proceeding		
1452 110	2452 55	2452 55	Petition to revive - unavoidable		
1453 1,330	2453 665	2453 665	Petition to revive - unintentional		
1501 1,370	2501 685	2501 685	Utility issue fee (or reissue)		
1502 490	2502 245	2502 245	Design issue fee		
1503 660	2503 330	2503 330	Plant issue fee		
1460 130	1460 130	1460 130	Petitions to the Commissioner		
1807 50	1807 50	1807 50	Processing fee under 37 CFR 1.17(q)		
1806 180	1806 180	1806 180	Submission of Information Disclosure Stmt		
8021 40	8021 40	8021 40	Recording each patent assignment per property (times number of properties)		
1809 790	2809 395	2809 395	Filing a submission after final rejection (37 CFR 1.129(a))		
1810 790	2810 395	2810 395	For each additional invention to be examined (37 CFR 1.129(b))		
1801 790	2801 395	2801 395	Request for Continued Examination (RCE)		
1802 900	1802 900	1802 900	Request for expedited examination of a design application		

SUBTOTAL (1) (\$)

Large Entity	Small Entity	Fee from Extra Claims below Fee Paid		
Total Claims		-20** =	X 18	=
Independent Claims		- 3** =	X 88	=
Multiple Dependent			300	=

SUBTOTAL (2) (\$)

\*or number previously paid, if greater; For Reissues, see above

Other fee (specify)


\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

130.00

### SUBMITTED BY


(Complete if applicable)

Name (Print/Type)	Mark Chao, Ph.D., JD	Registration No. (Attorney/Agent)	37,293
Signature		Date	12/12/04

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



# DUPLICATE

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)


Total Number of Pages in This Submission

Application Number	10/534,082
Filing Date	05/05/2005
First Named Inventor	S. Hinuma
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	3118 USOP

### ENCLOSURES (Check all that apply)


<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Return Postcard; Cert. Express Mailing;
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	<input type="checkbox"/> Copy of Executed Declaration
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> Copy of Executed Assignment + Cover Sheet
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> Statement of Submission
<input type="checkbox"/> <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<b>Remarks</b>	
The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 500799.		

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name			
Signature			
Printed name	Mark Chao, Ph.D., JD		
Date	12/12/05	Reg. No.	37,293

### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Gail L. Winokur	Date	12/12/05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Application No.:	10/534,082	Art Unit:	tba
Filed:	05/05/2005	Examiner:	tba
1 <sup>st</sup> Inventor:	S. Hinuma	Allowed:	
For:	Novel FPRLI Ligands and Use Thereof	Batch:	
Atty Dkt. No.	3118 USOP	Paper No.:	

The USPTO is requested to kindly acknowledge receipt of the following items:

1. This Postcard and Certificate of Express Mailing (2 pages)
2. Transmittal Form (1 page) and Fee Transmittal Form (1 page x 2)
3. Submission of Executed Declaration (1 page)
4. Copy of executed Declaration (7 pages)
5. Copy of executed Assignment and Recordation Cover Sheet & extra Fee Copy (4 pages)

Respectfully submitted 12/12/05 For Customer No. 23,115  
 Express Mail Label No. EV 617428041 US  
 By Mark Chao, PhD, JD - Reg. No. 37,293

372

Application No.:	10/534,082	Art Unit:	tba
Filed:	05/05/2005	Examiner:	tba
1 <sup>st</sup> Inventor:	S. Hinuma	Allowed:	
For:	Novel FPRLI Ligands and Use Thereof	Batch:	
Atty Dkt. No.	3118 USOP	Paper No.:	

The USPTO is requested to kindly acknowledge receipt of the following items:

1. This Postcard and Certificate of Express Mailing (2 pages)
2. Transmittal Form (1 page) and Fee Transmittal Form (1 page x 2)
3. Submission of Executed Declaration (1 page)
4. Copy of executed Declaration (7 pages)
5. Copy of executed Assignment and Recordation Cover Sheet & extra Fee Copy (4 pages)

Respectfully submitted 12/12/05 For Customer No. 23,115  
 Express Mail Label No. EV 617428041 US  
 By Mark Chao, PhD, JD - Reg. No. 37,293

JAP4 Rec'd PCT/PTO 12 DEC 2005

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.:	10/534,082	Art Unit:	tba
Filed:	05/05/2005	Examiner:	tba
1 <sup>st</sup> Inventor:	S. Hinuma	Allowed:	
For:	Novel FPRLI Ligands and Use Thereof	Batch:	
Atty. Dkt. No.	3118 USOP	Paper No.:	

**CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10**

**USPS EXPRESS MAIL LABEL. No. EV 617428041 US**

**DATE IN: December 12, 2005**

**Itemized Papers/Items:**


1. This certificate and a Return Receipt Postcard (2 pages)
2. Transmittal Letter (1 page) and Fee Transmittal (1 page X 2)
3. Submission of Executed Declaration (1 page)
4. Copy of executed Declaration (7 pages)
5. Copy of executed Assignment and Recordation Cover Sheet & extra Fee copy (4 pages)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on this date, December 12, 2005

Dated: 12/12/05

  
Gail L. Winokur

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
475 Half Day Road  
Lincolnshire, IL 60069 USA

**DUPLICATE**

**EV617428041US**